CDK2 inhibitors and methods of using the same

US12065445B2 · kind B2 · utility

Assignee

• Cedilla Therapeutics, Inc.

Inventors

• Louise Kirman · Cambridge, US
• Carl Eric Schwartz · Lynnfield, US
• Wojtek Michowski · Worthington, US
• Dale Porter · Cambridge, US
• Justin Ripper · Adelaide, AU
• John Thomas Feutrill · Waltham, US
• John Paul Sherrill · Melrose, US
• Thomas P. Blaisdell · Watertown, US

Key dates

• Filing date: Jan 28, 2022
• Grant date: Aug 20, 2024
• Expiry date: Jan 28, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides compounds according to Formula I or a pharmaceutically acceptable salt thereof: wherein each variable is as defined and described herein, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.